Literature DB >> 19604329

Pathogenesis and symptomatology of hallucinations (delusions) of organic brain disorder and schizophrenia.

Jun Horiguchi1, Tsuyoshi Miyaoka, Hideto Shinno.   

Abstract

In this review article, in order to explore the mechanisms underlying the hallucinations/delusions of schizophrenia, we discuss the contribution of the following four questions: (i) can an understanding of dreams contribute to our understanding of the genesis of halluciations and/or delusions; (ii) are the mechanisms underlying psychotropic drug-induced psychoses the same as those underlying the hallucinations and/or delusions in schizophrenia; (iii) does disturbed consciousness contribute to the manifestation of psychotic features; and (iv) are the psychoses caused by organic brain disorders any different to the hallucinations and/or delusions seen in schizophrenia? We conclude that there is a strong association between drug-induced hallucinations or hallucinations associated with organic brain disorders and simple hallucinosis or fluctuations in arousal level. Because intermediate configurations and/or cross-staining phenomena exist for hallucinations and delusions, especially in schizophrenic disorders, it is difficult to isolate the hallucinations and to recognize them as being abnormal experiences.

Entities:  

Mesh:

Year:  2009        PMID: 19604329     DOI: 10.1111/j.1479-8301.2009.00282.x

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  2 in total

Review 1.  Secondary psychosis induced by metabolic disorders.

Authors:  Olivier Bonnot; Paula M Herrera; Sylvie Tordjman; Mark Walterfang
Journal:  Front Neurosci       Date:  2015-05-19       Impact factor: 4.677

Review 2.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.